Summary: Mike Riley, President, Catalent Biologics, will discuss the latest trends in ADC discovery and development, with a focus on how next generation pipelines are being shaped by payload and linker chemistry innovations, including those from Catalent’s award-winning SMARTag® ADC platform.

This article describes the benefits of transitioning from IV to SQ administration, considers the advantages of using PFSs, and explores challenges and solutions for transitioning from vials to PFS.

During this webinar, Catalent experts will discuss challenges associated with charged variants of biotherapeutic products, including monoclonal antibodies and fusion proteins.

Listen in as Mike and Darren share how new modalities and manufacturing technologies have altered the partnership landscape between developers and CDMOs.

Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.

Summary: Join us as our panel of experts discuss key manufacturing challenges for early and late-stage gene-enabled cell therapy programs, as well as how to overcome them through effective partnerships.

Summary: Learn more on considerations for choosing the right CDMO for your late-stage biotherapeutics programs in this interview with Stacey Treichler, Ph.D., Director, Head of Marketing & Strategy, BioModalities, Catalent Biologics.

Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 3 of 3 in the mRNA fireside chat series with Catalent’s experts).

Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 2 of 3 in the mRNA fireside chat series with Catalent’s experts).

Summary: Breaking New Ground: Turning mRNA into an Established Therapeutic Modality (Video 1 of 3 in the mRNA fireside chat series with Catalent’s experts).